Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 38.7849
- Book/Share 33.5765
- PB 7.3218
- Debt/Equity 0.5878
- CurrentRatio 1.0277
- ROIC 0.1371
- MktCap 592449554426.0
- FreeCF/Share 8.1108
- PFCF 30.0766
- PE 22.2745
- Debt/Assets 0.2406
- DivYield 0.0209
- ROE 0.3378
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | JNJ | Morgan Stanley | Equal Weight | Overweight | -- | $262 | Jan. 28, 2026 |
| Initiation | JNJ | Scotiabank | -- | Sector Outperform | -- | $230 | Nov. 13, 2025 |
| Upgrade | JNJ | Daiwa Securities | Neutral | Outperform | -- | $203 | Oct. 20, 2025 |
| Upgrade | JNJ | Wells Fargo | Equal Weight | Overweight | -- | $212 | Oct. 3, 2025 |
| Upgrade | JNJ | Guggenheim | Neutral | Buy | -- | $206 | Sept. 23, 2025 |
| Upgrade | JNJ | Erste Group | Hold | Buy | -- | -- | July 23, 2025 |
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
Johnson & Johnson: Rich History Of Excellence Poised To Endure
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Positive
Johnson & Johnson offers a compelling balance of growth, innovation, and shareholder returns. JNJ's robust financials, including a fortress-like balance sheet and consistent dividends, support its ability to drive growth and innovation. The company is well-diversified across thriving healthcare segments, with promising FDA approvals and strategic M&A initiatives enhancing its market position.
Read More
J&J Stock Up More Than 6% in a Month: Time to Buy, Sell or Hold?
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.
Read More
Johnson & Johnson halts late-stage E.coli vaccine trial after poor results
Published: February 13, 2025 by: New York Post
Sentiment: Negative
Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary effectiveness thresholds.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
Published: February 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson. ("J&J" or the "Company") (NYSE: JNJ).
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100